The named-patient exception just became a process

How an experimental drug reaches a patient before regulators approve it is a question about the access system, not the molecule. This week that system shifted: a one-patient exception for a next-generation obesity drug became a reviewable application pathway.

The architecture moved from a single named envelope to a process. Under the prior posture, a single 79-year-old patient received special access to Eli Lilly's retatrutide, and the door was effectively closed to everyone else. Under the new posture, other patients can apply, and a reviewer at Lilly decides. The drug is not approved. The trial is not over. What changed is who decides who walks through.

Wire copy will read "Lilly widens access to retatrutide," which sounds like a softening of the regulatory wall. The frame inverts. Widening here does not move the drug closer to market — in effect, a gatekeeper shift, changing who decides rather than the drug's regulatory status — is the reporter's reframe. Special-access programs sit beside the formal trial-and-approval process, not inside it, and access under review is not the same as approval. The narrower reading treats a procedural change as a clinical one.

The same STAT+ roundup carries a second signal: the California Supreme Court ruled that drugmakers do not owe a "duty to innovate" to patients harmed by older medicines. Read together, the two items trace a single line. In this cycle, structural decisions about who gets experimental drugs and who bears the cost of older ones are moving through administrative and judicial channels faster than through the formal approval process itself.

That observation — the molecule is not the news; the decision about who gets to try it is — is the reporter's editorial thesis, not a sourced characterization.